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Treatment effects (improvements in HbA1c, hypoglycemic event
rates and changes in body weight) and cohort characteristics
(mean age 61.6 years, diabetes duration 13.2 years, HbA1c
8.2%, BMI 29.8 kg/m2) were taken from PREDICTIVE and
supplemented with Sweden speciﬁc patient data. Costs were
retrieved from published sources and expressed in 2005
Swedish Kronor (SEK) from both a third party payer and soci-
etal perspective. Total costs were projected over a 50-year time
horizon and discounted at 3% per annum. RESULTS: Over
patient lifetimes IAsp treatment was associated with lower
mean direct medical costs per patient of approximately SEK
8,248 per patient versus HI (SEK 405,910  16,358 versus
SEK 414,158  15,544 respectively). Savings were due to
reduced costs associated with diabetes-related complications
for IAsp compared to HI (difference SEK 14,886) despite
increased treatment and patient management costs (difference
SEK 6,641). Including indirect costs in the analysis increased
the cost savings associated with IAsp treatment to approxi-
mately SEK 10,717 (SEK 521,538  22,106 versus SEK
532,226  21,342). CONCLUSION: Over patient lifetimes,
IAsp treatment was projected to result in overall cost savings
compared to HI when accounting costs from both a health care
payer perspective and from a societal perspective in the Swedish
setting.
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OBJECTIVES: The aim of this study was to investigate the
annual use of medical resources (outpatient visits and current
drug use) and lost productivity (days off work) for people with
T2D with increasing BMI. METHODS: A retrospective analysis
was conducted in United States based on a sample of T2Ds
from the Adelphi Metabolic Syndrome Disease Speciﬁc Pro-
gramme (a large cross sectional study) in 2006 with 643 people
diagnosed with T2D, aged between 35 to 64 years and a
BMI°Ý 20 kg/m2 (based on physician reported height and
weight). People were stratiﬁed according to their BMI; normal/
overweight (20–29.99 kg/m2; n = 110), obese (30–34.99 kg/m2;
n = 178)); very obese (35–39.99 kg/m2; n = 170) and morbidly
obese (>39.99 kg/m2; n = 185). The cohort had an average age
of 53 years, 58% male, and 69% Caucasians. RESULTS: For
people with T2D who was normal/overweight, mean number of
total drugs used for any condition was 4.7. The number of
annual visits to health professionals (PCP, cardiologist, diabetes
specialist, diabetes nurse, other doctor/nurse) was 5.9. The rate
ratio i.e. the mean resource utilization relative to the utilization
in the normal/overweight group for people with T2D who was
obese, very obese and morbidly obese, respectively, were 1.08,
1.15, and 1.32 for total drug use, 1.75, 2.37, and 3.37 for
percentage of people using more than 2 diabetes drugs, and
1.21, 1.31, and 1.39 for annual number of visits to health pro-
fessionals. People not retired had an average annual number of
days off work due to CV or diabetes complications of 1.5 for
the normal/overweight group, with 3.2 for the obese group.
CONCLUSION: These ﬁndings suggest a positive correlation
between BMI and medical resources. The impact of obesity on
resource use is particularly evident in people with T2D in the
high obesity groups.
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OBJECTIVES: In the UK, the role of insulin initiation has tradi-
tionally been one for specialist (secondary care) diabetes teams
(SDT) but this trend is changing with primary care increasingly
taking a leading role. In order to appropriately plan services, all
relevant costs need to be considered. This analysis compares the
estimated costs of insulin initiation using different models of
service delivery—combinations of primary vs secondary care ini-
tiation and group vs individual sessions. METHODS: Using pub-
lished UK literature, the resources used for 4 different service
models were estimated, associated unit costs attached and
total costs estimated over the ﬁrst 3 months of insulin therapy.
RESULTS: In the secondary care led models, average costs were
£221 per person for an individual start over the 3 month period.
As expected, estimated costs for group start sessions were lower
than for individual starts (average £187). In a primary care
initiation model, the average per patient costs were only slightly
lower (£139 individual start, £190 group start). These costs are
higher than the costs of the insulin therapy over the same time
period (average £120) and key cost components were resources
of associated health care professionals (HCP) and length of ses-
sions with the relevant HCP, commonly assumed to be a diabetes
specialist nurse CONCLUSION: Details of the range of resources
used at the point of insulin initiation are not readily available in
the literature. This analysis suggests that signiﬁcant resources are
required compared with the medication costs over this initiation
period. The amount of time spent with the range of appropriate
HCPs is the key driver of cost. Many other factors need consid-
eration when deciding upon appropriate service models including
the experience of the HCPs, the complexity of the insulin regimen
and the degree of self-ownership and satisfaction by the patient.
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OBJECTIVES: In the long term there is a high rate of sulphony-
lurea (SU) prescription on oral antidiabetics (OAD) in Slovakia
compared to DM treatment standards in other countries.
Although this rate is decreasing slowly, there is a need to force the
prescription habits improvement in diabetic patients. Our objec-
tive was to use collected data and analyse prescription habits
of diabetologists with a focus on SU and biguanides rate.
METHODS: We used claims data of reimbursed medicines in
2005 of one Slovak health insurance fund. Diabetic patient was
identiﬁed as the one with at least two prescriptions regarding
DM diagnosis on annual basis. SU rate compared to the total SU
and metformin prescription was calculated for each diabetologist
on the basis of expenditure in DDDs. RESULTS: We identiﬁed
13,481 diabetics (7% of total DM patients undergoing pharma-
cotherapy in Slovakia). These patients were treated by 212
diabetologists. Average SU verus biguanides rate was 59%.
Worldwide, this rate stands for approximately 40%. This differ-
ence requires further steps so the doctors were categorized in
deciles for purposes of targeted audit. Furthermore, we calcu-
lated the savings if patients would go to biguanides instead of SU.
CONCLUSION: Claims data are an effective tool for auditing of
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prescription habits. Our study conﬁrmed the difference in pre-
scription habits and results should be disclosed to prescribers.
Mutual co-operation of health insurance and specialists on
similar analyses and quality indexes speciﬁcations has a great
potential to change the treatment patterns and could lead
to signiﬁcant savings when followed by direct feedback and
education.
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OBJECTIVES: Diagnosis of diabetes mellitus is the 4th in drug
spending in Slovakia. Our objective was to explore drug costs for
diabetes and pharmacotherapy break down costs on antidiabet-
ics as well as the complications or co-morbidities prevalence and
treatment. Drug consumption was compared for diabetic and
non-diabetic patients. METHODS: We used claims data of reim-
bursed medicines in the y.2005 of one private health insurance
fund. Diabetic patient was identiﬁed as the one with at least two
prescriptions regarding DM diagnosis on annual basis. We com-
pared prescription on the ATC3 level in costs and also in DDDs
for diabetic and non-diabetic patients regarding the age group
(analysis done for each age decade). RESULTS: We identiﬁed
13.481 diabetics /DM/ representing 7% of total diabetic patients
undergoing pharmacotherapy in Slovakia. All other policyhold-
ers with prescriptions were included into the control group /non-
DM/. The highest number of diabetic patients belongs to the age
group of 50–59. Average annual drug cost per patient was: 655
EUR for DM versus 127 EUR for non-DM, what represents
about 355% higher costs for DM. In drug costs of DM2 treat-
ment antidiabetics represent 33% and other pharmacotherapy
stands for 67%. Three leading ATC3 in reimbursed costs per
diabetic patient were: C10A, C09A and A16A. The main differ-
ences in drug use prevalence except antidiabetics occur in the
following drug groups: C09A ACE plain inhibitors (50% of DM
versus 10% of non-DM with prescription); B01A antithrombot-
ics (46% DM versus 9% non-DM) and C10A cholesterol and
triglyceride reducers (40% DM versus 6% non-DM). CONCLU-
SION: DM diagnosis implies a relevant economic impact. Besides
diabetics, the main cost driver is a cardiovascular treatment. This
analysis will be followed by evaluation of the rationality in the
prescription among diabetologists and could be the base for
other pharmacoeconomic studies.
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OBJECTIVES: To assess the differences between patient charac-
teristics of Type 2 diabetic patients that add sulfonylurea (SU) vs.
glitazone(PPAR) to ongoing metformin(MF) to attain adequate
glycemic control in the real life practice settings in UK.
METHODS: Retrospective clinical chart review and patient
survey at the point of visit were conducted among patients aged
°Ý30 year at time of diagnosis of T2 DM and added a SU or
PPAR to MF mono-therapy in UK from Dec 2006 to Jan 2007.
The information of each patient on HbA1c, medication use,
co-morbid conditions was collected for the 7-month baseline
period (on MF monotherpy) and the minimum a year follow-up
period (since the addition of SU or PPAR to MF). RESULTS:
Data from 412 patients (52% initially added SU to MF and 48%
added PPAR) was collected. For the SU+MF and PPAR+MF
groups respectively: mean age on MF alone was 60.8(SD = 11.2)
and 59.6(SD = 11.8) years; age at diagnosis was 56.2(SD = 10.8)
and 54.5(SD = 11.7) years; A1C prior to addition of SU or PPAR
was 8.6(SD = 1.5) and 8.6(SD = 1.4); The following variables
between the SU+MF and PPAR+MF groups respectively showed
signiﬁcant differences between the two groups: Weight 85.8 kg
(SD = 18.9) and 90.1 kg (SD = 19.0); BMI was 30.4 (SD = 6.5)
and 31.8 (SD = 7.0); % with Ischemic Heart Disease was 25.7%
and 16.6%; % with MI was 11.8% and 5%; mean total choles-
terol was 5.09 mmol/L (SD = 1.1) and 4.7 mmol/L (SD = 1.1);
mean LDL was 2.8 mmol/L (SD = 1.0) and 2.5 mmol/L
(SD = 1.1). Adjusted logistic regression showed that a lower total
cholesterol value (OR = 0.71 95%CI = 0.58–0.87) was associ-
ated with PPAR added to MF compared to SU patients. CON-
CLUSION: In this study population half of the patients added
PPAR to ongoing MF monotherapy. Patients adding PPAR to MF
tended to have lower cholesterol levels.
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OBJECTIVES: Treatment discontinuation may occur from a
variety of reasons. The purpose of this study was to characterise
treatment discontinuation in people who used either insulin
lispro, other short acting insulin (SAI) analogues’, or soluble
regular human insulin (RHI). METHODS: Data were extracted
from the GPRD, a resource that describes the primary care
histories of around 7% of the UK population. Subjects were
selected having been treated with one SAI. Cox proportional
hazard models (CPHM) were used to determine relative treat-
ment duration since these data were censored. A variety of cova-
riates were considered. RESULTS: We identiﬁed 7,958 subjects:
31% SAI analogue, 25% lispro and 44% RHI. Of these, 68.2%
had T1DM. In type 1 diabetes (T1DM) the mean age was 36.4
years (sd. 17.6) years with 45% female. In T2DM, the mean age
was 55.8 years (sd. 13.7) with 46% female. Regarding type 1
diabetes; the median treatment duration with a SAI regimen
was 11.6 years. Relative to RHI, the hazard ratio (HR) of dis-
continuation was 24.6% worse using other SAI analogue regi-
ments (p < 0.001), and 25.1% better with lispro (p < 0.001).
Gender—being male—was the only other signiﬁcant factor
(HR = 0.798; p < 0.001). Regarding type 2 diabetes; the median
treatment duration with a SAI regimen was 5.6 years. Relative to
RHI, the hazard ratio (HR) of discontinuation was 21.1% worse
using other SAI analogue regiments (p < 0.008), and 25.7%
better with lispro (p < 0.001). Age at SAI regimen initiation was
the only other signiﬁcant factor in the T2DM discontinuation
model (HR = 1.011; p < 0.001). CONCLUSION: There was a
discernable pattern to treatment discontinuation in people
treated with alternative SAI regimens. Insulin lispro resulted in
less likelihood of switching treatment. Gender was an important
predictor of treatment discontinuation in T1DM and subject age
at initiation in T2DM.
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